TY - JOUR AU - Brenner, D. R. AU - Weir, H. K. AU - Demers, A. A. AU - Ellison, L. F. AU - Louzado, C. AU - Shaw, A. PY - 2020 DA - 2020// TI - Projected estimates of cancer in Canada in 2020 JO - CMAJ VL - 192 UR - https://doi.org/10.1503/cmaj.191292 DO - 10.1503/cmaj.191292 ID - Brenner2020 ER - TY - STD TI - Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Vol. 3, Cancers. Multidisciplinary Digital Publishing Institute (MDPI); 2011. p. 3279–330. ID - ref2 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Ledermann, J. A. AU - Selle, F. AU - Gebski, V. AU - Penson, R. T. AU - Oza, A. M. PY - 2017 DA - 2017// TI - Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30469-2 DO - 10.1016/S1470-2045(17)30469-2 ID - Pujade-Lauraine2017 ER - TY - JOUR AU - Robson, M. AU - Im, S. A. AU - Senkus, E. AU - Xu, B. AU - Domchek, S. M. AU - Masuda, N. PY - 2017 DA - 2017// TI - Olaparib for metastatic breast cancer in patients with a germline BRCA mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1706450 DO - 10.1056/NEJMoa1706450 ID - Robson2017 ER - TY - JOUR AU - Golan, T. AU - Hammel, P. AU - Reni, M. AU - Cutsem, E. AU - Macarulla, T. AU - Hall, M. J. PY - 2019 DA - 2019// TI - Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1903387 DO - 10.1056/NEJMoa1903387 ID - Golan2019 ER - TY - STD TI - LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Vol. 20, The Lancet Oncology. Lancet Publishing Group; 2019. p. e15–28. ID - ref6 ER - TY - STD TI - Canada A. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION LYNPARZA ® olaparib capsules 50 mg Antineoplastic agent [Internet]. 2020. ID - ref7 ER - TY - STD TI - Solensky R, Khan DA, Contributors Leonard Bernstein WI, Bloomberg GR, Castells MC, Mendelson LM, et al. Drug allergy: An updated practice parameter. Ann Allergy, Asthma Immunol. 2010;105(4). ID - ref8 ER - TY - JOUR AU - Sloane, D. AU - Govindarajulu, U. AU - Harrow-Mortelliti, J. AU - Barry, W. AU - Hsu, F. I. AU - Hong, D. PY - 2016 DA - 2016// TI - Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies JO - J Allergy Clin Immunol Pract VL - 4 UR - https://doi.org/10.1016/j.jaip.2015.12.019 DO - 10.1016/j.jaip.2015.12.019 ID - Sloane2016 ER - TY - STD TI - Grabowski JP, Sehouli J, Glajzer J, Worm M, Zuberbier T, Fluhr JW. Olaparib desensitization in a patient with recurrent peritoneal cancer. Vol. 379, New England Journal of Medicine. Massachusetts Medical Society; 2018. p. 2176–7. ID - ref10 ER - TY - STD TI - Food and Drug Administration. FDA approves of olaparib tablets for maintenance treatment in ovarian cancer [Internet]. 2017. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer. UR - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer ID - ref11 ER -